| 阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效及其与血清TNF-α变化的关系 |
| 投稿时间：2010-04-22 点此下载全文 |
| 引用本文：高海兵,林明华,潘晨,林太杰,郑玲,原津津,方建凯,周锐.阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效及其与血清TNF-α变化的关系[J].医学研究杂志,2010,39(10):65-68 |
| DOI：
|
| 摘要点击次数: 1087 |
| 全文下载次数: 1008 |
|
| 基金项目:福州市社会发展科技项目(2008-s-74) |
|
| 中文摘要:目的分析阿德福韦酯(ADV)治疗HBeAg阳性慢性乙型肝炎(CHB)的疗效及其与血清TNF-α水平变化的关系。方法对203例HBeAg阳性CHB患者采用ADV（名正）10mg/d治疗48周，观察24周和48周疗效，包括HBV DNA转阴、ALT复常、HBeAg转阴及血清转换、应答率，并用ELISA测定基线及48周血清TNF-α水平。结果203例患者24周和48周HBV DNA转阴率、ALT复常率、HBeAg转阴率及血清转换率、应答率分别为31.5%、59.1%、15.8%、8.9%、13.3%和58.6%、783%、29.6%、16.7%、25.6%。24周和48周HBV DNA载量较基线下降的中位值分别是3.56log10拷贝/毫升和4.35log10拷贝/毫升，且48周疗效均优于24周（P＜0.05），而除HBV DNA未转阴组、ALT未复常组外，余疗效组TNF-α水平在48周较基线均下降明显(P＜0.001)。结论HBeAg阳性CHB患者ADV治疗48周能够有效地抑制HBV，降低血清TNF-α水平。 |
| 中文关键词:肝炎 乙型 慢性 阿德福韦酯 肿瘤坏死因子α 疗效 |
| |
| Study on Efficacy of Adefovir dipivoxil in HBeAg-positive Chronic Hepatitis B Patients and its Correlation with Serum Levels of Tumor Necrosis Factor α |
|
|
| Abstract:ObjectiveTo investigate the efficacy of Adefovir dipivoxil in HBeAg-positive chronic hepatitis B(CHB) patients and study its correlation with serum levels of tumor necrosis factor α.Methods203 HBeAg-positive CHB patients were recruited into the study and were administered with ADV(Minzhen) 10mg once daily for 48 weeks.The efficacy including HBV DNA negativity,alanine aminotransferase(ALT) normalization, HBeAg loss and seroconversion,and response at the treatment times of 24 and 48 weeks were observed.The serum levels of TNF-α at baseline and week 48 were examined by enzyme linked immunosorbent assay.ResultsThe rate of HBV DNA negativity,ALT normalization,HBeAg loss and seroconversion,and response in patients at the treatment times of 24 and 48 weeks were 31.5%, 59.1%, 15.8%, 8.9%, 13.3% and 58.6%, 78.3%, 29.6%, 16.7%, 25.6% respectively.And meantime the median reduction in serum HBV DNA loads was 3.56log10 and 4.35log10 copies/ml respectively.Furthermore the therapeutic effects at week 48 were all considerably better than those at week 24 (P＜0.05).There were lower serum levels of TNF-α at week 48 than before treatment in different therapeutic effect groups,which had statistic difference (P＜0.001).ConclusionADV can effectively inhibit the copy of HBV,depress serum levels of TNF-α during the treatment times of 48 weeks in patients with HBeAg-positive chronic hepatitis B. |
| keywords:Chronic hepatitis B Adefovir dipivoxil Tumor necrosis factor α Efficacy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
